Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
225 stopped studies mapped to Neuroendocrine Carcinoma and descendants · 90% state a reason
Over the 225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01722292 | A Study of LY2940680 in Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Nov 6, 2012 | Eli Lilly and Company | Change in clinical strategy. | Sponsor / business decision |
| NCT03334487 | Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment… | Phase 3 | withdrawn | Nov 7, 2017 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome… | Phase 1 / Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Terminated due to slow accrual,primary endpoint reached \& investigator left NIH. | Investigator |
| NCT03366675 | AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] | Phase 2 | terminated | Dec 8, 2017 | Samsung Medical Center | Early detection of the purpose of the study. | Other (stated, no rule matched) |
| NCT00702962 | Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive… | Phase 1 / Phase 2 | terminated | Jun 20, 2008 | Milton S. Hershey Medical Center | Poor accrual | Enrollment / accrual |
| NCT02500914 | SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma | Phase 1 | terminated | Jul 17, 2015 | Stemcentrx | Strategic Considerations | Sponsor / business decision |
| NCT02688907 | Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer… | Phase 2 | terminated | Feb 23, 2016 | Samsung Medical Center | change regimen | Other (stated, no rule matched) |
| NCT03106155 | Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring…([SUKSES-D]) | Phase 2 | terminated | Apr 10, 2017 | Samsung Medical Center | Decision of IP support organization | Other (stated, no rule matched) |
| NCT02011087 | Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With… | N/A | terminated | Dec 13, 2013 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT01325753 | Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or… | N/A | withdrawn | Mar 30, 2011 | Wake Forest University Health Sciences | not stated | Not stated |
| NCT02331251 | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Phase 1 / Phase 2 | terminated | Jan 6, 2015 | Western Regional Medical Center | PI not longer at site. | Other (stated, no rule matched) |
| NCT02748889 | Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small… | Phase 1 / Phase 2 | terminated | Apr 22, 2016 | Giuseppe Giaccone | Difficulties with recruitment | Enrollment / accrual |
| NCT02161419 | RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer(CONCEPT-SCLC) | Phase 2 | terminated | Jun 11, 2014 | Bayer | not stated | Not stated |
| NCT02250404 | Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung… | — | withdrawn | Sep 26, 2014 | University of Southern California | PI left institution | Investigator |
| NCT02054884 | F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma | Phase 2 | terminated | Feb 4, 2014 | Philogen S.p.A. | Lack of enrollment | Enrollment / accrual |
| NCT02261805 | A Phase I/II Study of Ganetespib in Combination With Doxorubicin | Phase 1 / Phase 2 | terminated | Oct 10, 2014 | Georgetown University | Company terminated drug support | Sponsor / business decision |
| NCT01188486 | Pulmonary Interstitial Lymphography in Early Stage Lung Cancer | N/A | terminated | Aug 25, 2010 | Stanford University | Business decision | Sponsor / business decision |
| NCT00265200 | Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer | Phase 2 | terminated | Dec 14, 2005 | University of Louisville | funding discontinued by sponsor | Funding |
| NCT01237678 | A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell… | Phase 1 / Phase 2 | terminated | Nov 9, 2010 | ImmunoGen, Inc. | Study was stopped early due to lack of efficacy signal and safety concerns | Safety / toxicity |
| NCT02297087 | Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for… | N/A | terminated | Nov 21, 2014 | Western Regional Medical Center | PI no longer at site and he does | Other (stated, no rule matched) |
| NCT00003496 | Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell… | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | slow accrual | Enrollment / accrual |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and… | Phase 1 | withdrawn | Jul 13, 2016 | Vanderbilt-Ingram Cancer Center | Loss of funding support | Funding |
| NCT02876081 | Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV…(THEN) | Phase 2 | withdrawn | Aug 23, 2016 | Fondation Hôpital Saint-Joseph | medical decision | Other (stated, no rule matched) |
| NCT02715102 | Circulating Tumor DNA in Patients at High Risk for Lung Cancer | — | terminated | Mar 22, 2016 | Pathway Genomics | Patient accrual was slow due to exclusion of patients with prior cancers | Enrollment / accrual |
| NCT02425072 | NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer | Phase 2 | withdrawn | Apr 23, 2015 | John Villano | slow accrual | Enrollment / accrual |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | Phase 2 | withdrawn | Apr 9, 2014 | Academic and Community Cancer Research United | not stated | Not stated |
| NCT01575782 | Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung…(Chloroquine) | Phase 1 | terminated | Apr 11, 2012 | Maastricht Radiation Oncology | Poor accrual | Enrollment / accrual |
| NCT00454324 | Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer(NRR) | Phase 2 | terminated | Mar 30, 2007 | UNC Lineberger Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT00958022 | Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer | Phase 1 | terminated | Aug 13, 2009 | Ahmad Tarhini | Based on the tolerabilty challenges of the combination | Other (stated, no rule matched) |
| NCT00129974 | Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage… | Phase 2 | terminated | Aug 12, 2005 | Tufts Medical Center | failure to accrue | Enrollment / accrual |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT01758458 | Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma | Phase 1 / Phase 2 | terminated | Jan 1, 2013 | Fred Hutchinson Cancer Center | A Phase I/II study (NCT01758458) is now recruiting | Enrollment / accrual |
| NCT01719861 | Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors | Phase 2 | terminated | Nov 1, 2012 | Joel Neal | Lack of efficacy | Efficacy / futility |
| NCT01640847 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of… | Phase 2 | withdrawn | Jul 16, 2012 | Imunon | not stated | Not stated |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic… | Phase 2 | terminated | Oct 24, 2014 | Emory University | Slow accrual | Enrollment / accrual |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously… | Phase 1 / Phase 2 | withdrawn | Jan 22, 2016 | Case Comprehensive Cancer Center | Drug unavailable | Other (stated, no rule matched) |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Phase 1 | terminated | Apr 11, 2013 | Mirna Therapeutics, Inc. | Five immune related serious adverse events | Safety / toxicity |
| NCT01137162 | Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors | — | terminated | Jun 4, 2010 | Stanford University | Low Accrual | Enrollment / accrual |
| NCT02152059 | A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer… | Phase 2 | withdrawn | Jun 2, 2014 | AHS Cancer Control Alberta | contract issues | Other (stated, no rule matched) |
| NCT02351505 | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | Phase 2 | terminated | Jan 30, 2015 | Erin Bertino | Low patient accrual | Enrollment / accrual |
| NCT00812266 | Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of… | Phase 3 | terminated | Dec 22, 2008 | Danish Oncological Lung Cancer Group | Slow accrual | Enrollment / accrual |
| NCT00299390 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer | Phase 2 | terminated | Mar 6, 2006 | Bayer | Since only 1 of the first 10 subjects responded to the study treatment, it was decided to stop the… | Efficacy / futility |
| NCT01159327 | Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction… | Phase 2 | terminated | Jul 9, 2010 | National Cancer Center, Korea | low enrolling participants | Enrollment / accrual |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | Phase 2 | withdrawn | Sep 28, 2005 | Eastern Cooperative Oncology Group | not stated | Not stated |
| NCT00755157 | Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer | Phase 2 | withdrawn | Sep 18, 2008 | University Hospital of Crete | not stated | Not stated |
| NCT01487499 | Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)(SCLC) | Phase 3 | terminated | Dec 7, 2011 | University of Florida | Unable to enroll adequate number of participants | Enrollment / accrual |
| NCT01421316 | Hair-sparing Whole Brain Radiotherapy | Phase 2 | terminated | Aug 22, 2011 | University Hospital, Ghent | No reduction in hair loss 1 month after treatment | Other (stated, no rule matched) |
| NCT01486459 | A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing…(TULIP) | N/A | terminated | Dec 6, 2011 | Barwon Health | Insufficient recruits | Enrollment / accrual |
| NCT01591512 | A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer | — | terminated | May 4, 2012 | Fujirebio Diagnostics, Inc. | Decision was made by Sponsor to stop the trial. | Other (stated, no rule matched) |
| NCT01886287 | P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome | Phase 2 | terminated | Jun 25, 2013 | H. Lee Moffitt Cancer Center and Research Institute | Slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Dec 28, 2018source: clinicaltrials